132 related articles for article (PubMed ID: 38185192)
1. GLP-1 derivatives with functional sequences transit and migrate through trigeminal neurons.
Akita T; Shimamura M; Tezuka A; Takagi M; Yamashita C
Eur J Pharm Biopharm; 2024 Feb; 195():114176. PubMed ID: 38185192
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2.
Akita T; Kimura R; Akaguma S; Nagai M; Nakao Y; Tsugane M; Suzuki H; Oka JI; Yamashita C
J Control Release; 2021 Jul; 335():575-583. PubMed ID: 34116136
[TBL] [Abstract][Full Text] [Related]
3. Involvement of trigeminal axons in nose-to-brain delivery of glucagon-like peptide-2 derivative.
Akita T; Oda Y; Kimura R; Nagai M; Tezuka A; Shimamura M; Washizu K; Oka JI; Yamashita C
J Control Release; 2022 Nov; 351():573-580. PubMed ID: 36179766
[TBL] [Abstract][Full Text] [Related]
4. [Improving Effects of Peptides on Brain Malfunction and Intranasal Delivery of Those Derivatives to the Brain].
Oka JI
Yakugaku Zasshi; 2019; 139(5):783-791. PubMed ID: 31061348
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant-like effects exerted by the intranasal administration of a glucagon-like peptide-2 derivative containing cell-penetrating peptides and a penetration-accelerating sequence in mice.
Sasaki-Hamada S; Nakamura R; Nakao Y; Akimoto T; Sanai E; Nagai M; Horiguchi M; Yamashita C; Oka JI
Peptides; 2017 Jan; 87():64-70. PubMed ID: 27894924
[TBL] [Abstract][Full Text] [Related]
6. [Nose-to-Brain Delivery of Peptide Drugs Enhanced by Coadministration of Cell-penetrating Peptides: Therapeutic Potential for Dementia].
Kamei N
Yakugaku Zasshi; 2017; 137(10):1247-1253. PubMed ID: 28966266
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
During MJ; Cao L; Zuzga DS; Francis JS; Fitzsimons HL; Jiao X; Bland RJ; Klugmann M; Banks WA; Drucker DJ; Haile CN
Nat Med; 2003 Sep; 9(9):1173-9. PubMed ID: 12925848
[TBL] [Abstract][Full Text] [Related]
8. Effect of an Enhanced Nose-to-Brain Delivery of Insulin on Mild and Progressive Memory Loss in the Senescence-Accelerated Mouse.
Kamei N; Tanaka M; Choi H; Okada N; Ikeda T; Itokazu R; Takeda-Morishita M
Mol Pharm; 2017 Mar; 14(3):916-927. PubMed ID: 28094952
[TBL] [Abstract][Full Text] [Related]
9. Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction.
Kamei N; Okada N; Ikeda T; Choi H; Fujiwara Y; Okumura H; Takeda-Morishita M
Sci Rep; 2018 Dec; 8(1):17641. PubMed ID: 30518944
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites.
Yamamoto H; Kishi T; Lee CE; Choi BJ; Fang H; Hollenberg AN; Drucker DJ; Elmquist JK
J Neurosci; 2003 Apr; 23(7):2939-46. PubMed ID: 12684481
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-2 rescues memory impairments and neuropathological changes in a mouse model of dementia induced by the intracerebroventricular administration of streptozotocin.
Sasaki-Hamada S; Ikeda M; Oka JI
Sci Rep; 2019 Sep; 9(1):13723. PubMed ID: 31548563
[TBL] [Abstract][Full Text] [Related]
12. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.
Larsen PJ; Tang-Christensen M; Jessop DS
Endocrinology; 1997 Oct; 138(10):4445-55. PubMed ID: 9322962
[TBL] [Abstract][Full Text] [Related]
13. The incretin hormone glucagon-like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage-dependent potassium channel.
Thiebaud N; Llewellyn-Smith IJ; Gribble F; Reimann F; Trapp S; Fadool DA
J Physiol; 2016 May; 594(10):2607-28. PubMed ID: 26931093
[TBL] [Abstract][Full Text] [Related]
14. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
15. Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport.
Lee J; Koehler J; Yusta B; Bahrami J; Matthews D; Rafii M; Pencharz PB; Drucker DJ
Mol Metab; 2017 Mar; 6(3):245-255. PubMed ID: 28271031
[TBL] [Abstract][Full Text] [Related]
16. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
Kamei N; Takeda-Morishita M
J Control Release; 2015 Jan; 197():105-10. PubMed ID: 25445695
[TBL] [Abstract][Full Text] [Related]
17. Intranasal administration of neuromedin U derivatives containing cell-penetrating peptides and a penetration-accelerating sequence induced memory improvements in mice.
Sasaki-Hamada S; Funane T; Nakao Y; Sasaki R; Nagai M; Ueta Y; Yoshizawa K; Horiguchi M; Yamashita C; Oka JI
Peptides; 2018 Jan; 99():241-246. PubMed ID: 29079533
[TBL] [Abstract][Full Text] [Related]
18. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake.
Navarro M; Rodriquez de Fonseca F; Alvarez E; Chowen JA; Zueco JA; Gomez R; Eng J; Blázquez E
J Neurochem; 1996 Nov; 67(5):1982-91. PubMed ID: 8863504
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide.
Blázquez E; Alvarez E; Navarro M; Roncero I; Rodríguez-Fonseca F; Chowen JA; Zueco JA
Mol Neurobiol; 1998 Oct; 18(2):157-73. PubMed ID: 10065878
[TBL] [Abstract][Full Text] [Related]
20. [Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus].
Nakazato M
Nihon Rinsho; 2011 May; 69(5):918-22. PubMed ID: 21595282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
